Navigation Links
The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients

t data and treatment protocols every two years.

VELCADE has been available to patients, who have relapsed after a previous treatment, in the United States since 2003 and in Europe since 2004. VELCADE as a single agent shows a median overall survival in this patient population of two and a half years (29.8 months) with "robust response rates" regardless of age. VELCADE in combination with DOXIL(R) was approved in May 2007. Data from a follow-up to a Phase 3 multi-national clinical trial shows that this combination further improves the probability of survival by 41%. Among the findings presented from an open label Phase I/II study evaluating 54 patients, when VELCADE is combined with melphalan and prednisone in newly diagnosed patients who do not go on to have transplants, survival was 85% the strongest 3 year survival rate demonstrated to date.

REVLIMID, an oral drug, is the newest of the novel therapies. This is the first conference since its European approval earlier this month; it is already approved in the United States for use in combination with dexamethasone as a treatment for multiple myeloma in patients who have been previously treated. Among the findings presented, in patients who have relapsed or not responded to a previous treatment, the 35 month median survival using REVLIMID in combination with dexamethasone has been characterized as the "highest response rate and longest overall survival" reported so far from two large randomized controlled Phase III trials that enrolled more than 700 patients worldwide. Importantly, it was previously reported that in patients newly diagnosed with multiple myeloma, in a large randomized Phase III trial evaluating more than 400 patients, REVLIMID with low dose dexamethasone demonstrated what has been called an "unprecedented" 98% one year survival in patients under 65 and 95% one year survival in patients 65 and over.

Combining these two powerful agents, VELCADE AND REVLIMID, produces "robust and du
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:7/23/2014)... July 23, 2014 Research and Markets ... Market in Consumer Healthcare by Application, Sensor Type & ... - 2020" report to their offering. ... been an increasing momentum for consumer healthcare monitoring and ... The consumer healthcare will lessen the healthcare cost of ...
(Date:7/23/2014)... , July 23, 2014 NOT ... DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE ... LAWS OR REGULATIONS OF SUCH JURISDICTION. AbbVie (NYSE: ... results on Friday, July 25, 2014, before the market opens. ... earnings conference call at 8 a.m. Central time (9 a.m. ...
(Date:7/23/2014)... 2014 Research and Markets   ... Electrophysiology Ablation Catheters Market 2014-2018" report to ... Catheter ablation is a minimally ... electrical pathways from sections of the heart that ... arrhythmias). Cardiac arrhythmias can be of several types, ...
Breaking Medicine Technology:Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 2Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 3AbbVie to Host Second-Quarter Earnings Conference Call 2AbbVie to Host Second-Quarter Earnings Conference Call 3AbbVie to Host Second-Quarter Earnings Conference Call 4AbbVie to Host Second-Quarter Earnings Conference Call 5AbbVie to Host Second-Quarter Earnings Conference Call 6Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3
... Inc. (NASDAQ: DCTH ) today announced ... ISO 13485:2003 Certification—an internationally recognized quality standard designed ... necessary comprehensive quality management systems in place to ... in the European Union (EU). ISO 13485 Certification ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Devices Market Outlook to 2017- Glucose ... http://www.reportlinker.com/p0739469/South-and-Central-America-Diabetes-Care-Devices-Market-Outlook-to-2017--Glucose-Monitoring-and-Insulin-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ...
Cached Medicine Technology:Delcath's Ireland Operations Achieves ISO 13485 Certification 2Delcath's Ireland Operations Achieves ISO 13485 Certification 3South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 2South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 3South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 4South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 5South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 6South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 7South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 8South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 9
(Date:7/23/2014)... A scientist from the University of Exeter has ... for diagnosing a frequently fatal lung disease which ... and bone marrow transplant recipients. , The lateral-flow ... invasive pulmonary aspergillosis, a notoriously difficult to diagnose ... , Invasive aspergillosis is a ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... If past experience is anything to go by, ... get a lot more recognition for their contributions to ... allowing NPs to provide primary care offer nurses more ... relationships with physicians and administrators, compared with colleagues in ... School of Nursing, published in Health Care Management ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July ... American children and teens look in the mirror and ... reported Wednesday. "Being overweight or obese is associated ... high cholesterol and diabetes," said lead researcher Neda Sarafrazi, ... Control and Prevention,s National Center for Health Statistics. ...
(Date:7/23/2014)... The next episode of “Extreme Weight Loss” Season ... physically fit through childhood and adolescence. After becoming pregnant ... decision to give her son up for adoption. That ... and she punished herself by overeating, gaining nearly 200 ... approach to weight loss transformations, “Extreme Weight Loss” airs ...
Breaking Medicine News(10 mins):Health News:New device detects deadly lung disease 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:New York law offers nurses more recognition, responsibility 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2
... Autism Speaks, the world,s largest autism science and ... top awards for "Autism Connects", the international student design ... competitors selected by a juried panel demonstrate creative technology ... better connect with the world around them, and allow ...
... News) -- People with allergies and asthma need to take ... Failure to remove contaminated materials and to reduce moisture and ... long-term health risks, according to the American College of Allergy, ... materials quickly lead to the growth of mold, a common ...
... (HealthDay News) -- Children have longer hospital stays if ... language skills, a U.S. study finds. The research, ... of Pediatrics & Adolescent Medicine , included almost 1,300 ... for treatment of infections requiring long-term antibiotics. Among ...
... 2011 The so-called "bad cholesterol" low-density lipoprotein ... shows a Texas A&M University study that casts new light on ... a researcher in the Department of Health and Kinesiology, says the ... health it has been made out to be in recent years ...
... today announced Horizon Pharma,s support of research awards ... through competition and recognition: AGA-Horizon ... $1,000 each to fellows who have submitted abstracts ... (DDW). , AGA-Horizon Pharma Student Abstract ...
... the University of North Carolina at Chapel Hill School of ... developing placenta, have given them the same properties of stem ... The scientific first opens the door for developing novel targeted ... TNBC, this is a highly recurrent tumor that spreads aggressively ...
Cached Medicine News:Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 2Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 3Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 4Health News:Parents' Limited English May Prolong Child's Hospital Stay 2Health News:'Bad' cholesterol not as bad as people think, shows Texas A&M study 2Health News:Horizon Pharma supports fellows and students with AGA Abstract Prizes 2Health News:Normal stem cells made to look and act like cancer stem cells 2
Inquire...
... inspects your equipment upon arrival. Our technician then ... provides you with a thorough customer quote. We ... tight budget so well help you prioritize repairs. ... begins., , ISI uses only OEM or widely ...
... Konelab 20XT analyzer is the newest addition ... analyzers and reagents, designed to meet the ... specialty clinical laboratories. The Konelab 20XT analyzer ... 20 and yet improves on the throughput, ...
... The Shandon Coverplate is a plastic device that ... to be immunostained with a minimum amount of ... to fill the gap between the coverplate and ... until the next reagent is dispensed into the ...
Medicine Products: